Clinical trials: Melanoma, Stage II
Metastatic Melanoma
RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
The primary objective is to determine the maximum tolerated hypofractionated radiotherapy dose (MTD) to a solitary metastatic focus ('index lesion') when followed by ipilimumab, in metastatic melanoma patients without brain…
- Trial name
- NCT01497808
- Testing
- Ipilimumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma (Skin)
Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00811759
- Testing
- sorafenib tosylate, temozolomide, gene expression analysis
- Where
- France
- Volunteers
- 58 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Gastric Adenocarcinoma, Malignant Melanoma
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
This study is a phase II study of AZD6738 in combination with durvalumab in patients with solid tumor (cohort A (N=30): GC who have failed secondary chemotherapy treatments regimen; cohort B (B=30): melanoma patients who have…
- Trial name
- NCT03780608
- Testing
- AZD6738, Durvalumab
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Samsung Medical Center
Adult Solid Tumor, Adenocarcinoma of the Colon
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
RATIONALE: PD 0332991 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well PD 0332991 works in treating patients with…
- Conditions
- Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor
- Trial name
- NCT01037790
- Testing
- PD-0332991
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma (Skin), Melanoma, Stage II, Stage I
Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma
A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app.
- Conditions
- Melanoma (Skin), Melanoma, Stage II, Stage I, Melanoma Stage, Survivorship
- Trial name
- Melanoma SCP (NCT06643286)
- Testing
- Digizorg Melanoma app
- Where
- 4 sites in Netherlands
- Volunteers
- 180 people
- Sponsor
- Erasmus Medical Center
Melanoma
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
This research is being done because melanoma in the brain is very difficult to treat because it does not respond to radiation or to chemotherapy, such as temozolomide.
- Trial name
- MEL0107 (NCT01048554)
- Testing
- Temozolomide, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Metastatic Melanoma, Mucosal Melanoma
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well nab-paclitaxel and bevacizumab or ipilimumab works as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery.
- Conditions
- Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
- Trial name
- NCT02158520
- Testing
- Bevacizumab, Ipilimumab, Laboratory Biomarker Analysis
- Where
- 13 sites in United States
- Volunteers
- 24 people
- Sponsor
- Academic and Community Cancer Research United
Mucosal Melanoma
Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era
In China, mucosal melanoma of head and neck (MMHN) account for 30-40% of all melanoma and the incidence is on the rise. The prognosis of MMHN is poor with the 5-year survival in a range between 20-30%.
- Trial name
- NCT03138642
- Testing
- RT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
This phase II trial studies the side effects and how well low dose ipilimumab works in combination with pembrolizumab in treating patients with melanoma that has spread to the brain.
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT03873818
- Testing
- Ipilimumab, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced BRAF Mutant Melanoma
Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
The primary purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with…
- Trial name
- BAMM (NCT02257424)
- Testing
- Trametinib 2 mg daily, hydroxychloroquine (HCQ), dabrafenib 150 mg orally twice a day
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Uveal Melanoma
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma.
- Trial name
- NCT06121180
- Testing
- ZIV-Aflibercept, Cemiplimab
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Melanoma
Taxoprexin Treatment for Advanced Skin Melanoma
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population.
- Trial name
- NCT00249262
- Testing
- Taxoprexin
- Volunteers
- 30 people
- Sponsor
- American Regent, Inc.